Krista Rossi

Positive phase 2b data from AbbVie’s upadacitinib demonstrated an induction for clinical remission in patients with ulcerative colitis.

A supplemental new drug application (sNDA) for vortioxetine (TRINTELLIX), a prescription medication for the treatment of adults with major depressive disorder (MDD), has been accepted by the FDA.

Stay up-to-date on the latest rare disease news by reading the top 5 articles of the week.

Not sure what’s been recalled, withdrawn from the market, or had safety updates? Catch up on the US Food and Drug Administration’s (FDA's) recalls and safety news from this past week.

A panel of members from the US Food and Drug Administration (FDA) sat down to discuss the influential factors and projective trajectory of the rare disease pipeline.

Members from the FDA came together to participate in an informative session and discuss the traditional pathway and future outlook of clinical trials in rare diseases.

The FDA has granted a priority review to combination therapy, ibrutinib/obinutuzumab, for the treatment of previously untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Receiving a proper diagnosis can be one of the greatest challenges for a rare disease patient, but having the right tools can help.

Although there have been many successes experienced in the oncology community, more genomic data is needed.

A panel at the NORD 2018 Summit discusses how patients are the catalysts behind rare disease research and drug development.

Mary Beth Scholand, MD, outlines the best treatment practices for idiopathic pulmonary fibrosis (IPF) to date and therapies worth investigating in the future.

Nicola Hanania, MD, MS, director of the Airways Clinical Research Center at Baylor College of Medicine, explains the latest research on COPD treatments and outlines how they all measure.

Data from a subgroup analysis of the IMPACT study, which compared inhale triple therapy FF/UMEC/VI to dual therapy FF/VI and UMEC/VI for the treatment of COPD, has been released.

FEF25-75 may be used as a parameter for early detection of beginning small airway obstruction in smokers with normal FEV1/FVC.

Novartis files new indication for ranibizumab (Lucentis) for the treatment of retinopathy of prematurity.

The central aims of the study are to better prepare for clinical trials by defining the best outcome measures for assessing how effective prospective therapies in dysferlinopathy are and to gain a stronger understanding of disease progression.

Investigators from the Nationwide Children’s Hospital assessed family history in relation to asthma control in pediatric patients.

A COPD care bundle delivered by a multidisciplinary health care team can reduce hospital readmission rates for acute exacerbations of COPD (AECOPD).

Montelukast/levocetirizine combination therapy demonstrates safety and efficacy in phase 3 clinical trial for the treatment of patients with perennial allergic rhinitis who have mild-to-moderate asthma.

There’s a challenge to achieve control in some asthma patients since the disease is heterogenous—both allergic and non-allergic triggers can initiate Type 2 inflammatory pathways that can drive pathology.

Joshua Denson, MD, MS, discusses the comorbidities associated with asthma.

Antonion R. Anzueto, MD, covers the latest research regarding biomarkers in COPD, outlining possible avenues of investigation and addressing regional causes of the disease.

Conflict management education intervention, which includes elements of compromise and awareness, helps improve ICU care.

Investigators from Brooke Army Medical Center discuss pharmacological and non-pharmacological treatment strategies for tobacco cessation.

Secondhand factors in asthma, such as environmental exposures like pets and secondhand smoke, are not significant in overall disease improvement.

Women are less likely to be administered lung protective tidal volumes (TVs) when being considered as a lung donor.

Data show that while women are underrepresented as fellows of the American College of Chest Physicians, the volume of women applying is increasing.

Stay up to date on the latest product recalls issued by the FDA this past week.

The FDA has approved inotersen (TEGSEDI) for the treatment of adults with the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

The FDA has approved elapegademase-lvlr injection (Revcovi) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.